Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
David A QuallsAriela NoyDavid J StrausMatthew J MatasarCraig H MoskowitzVenkatraman SeshanAhmet DoganGilles Andre SallesAnas YounesAndrew D ZelenetzConnie Lee BatleviPublished in: Leukemia & lymphoma (2023)
Keyphrases
- phase ii study
- open label
- locally advanced
- acute lymphoblastic leukemia
- acute myeloid leukemia
- dna methylation
- diffuse large b cell lymphoma
- multiple myeloma
- gene expression
- hodgkin lymphoma
- cancer therapy
- placebo controlled
- squamous cell carcinoma
- clinical trial
- rectal cancer
- stem cells
- randomized controlled trial
- bone marrow
- replacement therapy
- mesenchymal stem cells
- cell therapy